%0 Journal Article %T Hypoxia-Inducible Factor1-Α (HIF1α) and Vascular Endothelial Growth Factor-A (VEGF-A) Expression in De Novo AML Patients %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Jabari, Mohammad %A Allahbakhshian Farsani, Mehdi %A Salari, Sina %A Hamidpour, Mohsen %A Amiri, Vahid %A Mohammadi, Mohammad Hossein %D 2019 %\ 03/01/2019 %V 20 %N 3 %P 705-710 %! Hypoxia-Inducible Factor1-Α (HIF1α) and Vascular Endothelial Growth Factor-A (VEGF-A) Expression in De Novo AML Patients %K Keywords: Acute myeloid leukemia %K hypoxia %K HIF1α %K VEGF %R 10.31557/APJCP.2019.20.3.705 %X Background: Bone marrow hypoxia can promote leukemia progression in human cases of acute myeloid leukemia(AML). In addition, low oxygen tension is able to regulate the expression of different genes involved in malignancy.In this study, we hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF-A) genes wereassessed as principal regulators of hypoxia in do novo AML patients. Methods: Peripheral blood and bone marrowsamples were collected from 57 AML patients and 17 normal control subjects with informed consent. Expression ofHIF1α and VEGF-A was then evaluated using quantitative real-time PCR (Q-Real time PCR) and data were analyzedwith SPSS 16. Result: HIF1α and VEGF-A showed overexpression in AML patients compared to normal controls (PAML-non M3 cases. Furthermore, there was a positive correlation between HIF1α and VEGF-A ( P 0.497). Conclusion: Adding to the many studies on the role of hypoxia in solid tumors, our data indicate that HIF1aand VEGF-A overexpression also occurs in AML patients. We consider that this is possibly involved in leukemic cellgrowth and therefore could be a promising target for clinical control. %U https://journal.waocp.org/article_82375_6bc1104b5dbed5b00b4920c44e46c1b6.pdf